[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].

Qian Jiang, Donglu Zhao, Jian Jin, Wu Depei, Fan‐Yi Meng, Jian Hu, Biying Liu, Xin Du, Ting Liu, Li Y, Ming‐Feng Hou, Xingmin Han, Zhixiang Shen, Ma JPubMed 2015 · DOI

Abstract

Our results revealed the excellent early haematology, cytogenetic and molecular responses and safety of Xinwei in treating patients with CML-CP.
BibTeX
@inproceedings{jiang2015prospective,
  author = {Qian Jiang and Donglu Zhao and Jian Jin and Wu Depei and Fan‐Yi Meng and Jian Hu and Biying Liu and Xin Du and Ting Liu and Li Y and Ming‐Feng Hou and Xingmin Han and Zhixiang Shen and Ma J},
  title = {{[A prospective, multi-centre clinical trial to evaluate the early clinical efficacy and safety of a generic imatinib in treating patients with chronic phase of chronic myelogenous leukemia].}},
  booktitle = {PubMed},
  year = {2015},
  doi = {10.3760/cma.j.issn.0253-2727.2015.08.005},
}

Loading related content...

Figure